… apoA-I Milano (ETC-216) demonstrated a rapid regression of coronary atherosclerosis in
patients … to demonstrate a similar effect on coronary atherosclerosis. However, in the setting of …

… and modifications in patients with coronary artery disease [13, 14]. ApoA-I is the principal …
Recombinant apoA-I Milano produced in bacteria and complexed with phospholipids was …

… (sHDL) containing the recombinant form of apoA-I Milano (sHDL-apoA-I M ), originating …
increased atherosclerosis, has been largely proved in diverse animal models of atherosclerosis; …

… only apoA-I) and of LpA-I:A-II (particles containing both apoA-I … with commercial polyclonal
antibodies against human apoA-I. … with ACS, diabetes mellitus, coronary artery disease, and …

… , where the intravenous administration of recombinant apoA-IM has been … in patients with
acute coronary syndrome (ACS) found a significant regression of coronary atherosclerosis after …

… , a recombinant high–molecular mass variant of human apoA-I, named Tetranectin-apoA-I,
has been engineered by fusing 3 apoA-I … of a human apoA-I molecular variant, apoA-I Milano , …

… (CV) event rates among both patients with stable coronary artery disease and recent MI. …
of apoA-I. MDCO-216, a recombinant dimeric ApoA-I Milano, a mutant form of apoA-I, …

… of MDCO-216 in healthy volunteers and in patients with coronary artery disease (CAD). …
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary …

… acute MI patients with multivessel coronary artery disease and additional CV risk factors to
either 4 weekly infusions of apoA-I (… of the apoA-I Milano variant, and CER-001, a recombinant …

… and in patients with stable coronary artery disease (CAD). … MDCO-216 is a complex of highly
purified dimeric recombinant apoA-… The distribution of apoA-I, apoA-I Milano and apoE over …